Trial record 4 of 28 for:    "glucose-6-phosphate dehydrogenase deficiency"

A Test to Predict the Hemolytic Potential of Drugs in G6PD Deficiency

This study has been completed.
Information provided by:
Walter Reed Army Institute of Research (WRAIR) Identifier:
First received: January 20, 2004
Last updated: July 26, 2010
Last verified: July 2010
This study will evaluate a new and safe testing method for identifying medicines that can cause problems in glucose-6-phosphate dehydrogenase (G6PD) deficient individuals. We are looking for volunteers with G6PD deficiency who would be willing to donate blood samples.

Condition Intervention
Glucosephosphate Dehydrogenase Deficiency
Drug: Primaquine

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Endpoint Classification: Pharmacodynamics Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Prevention
Official Title: A New Test to Predict the Hemolytic Potential of Drugs in G6PD Deficiency

Resource links provided by NLM:

Further study details as provided by Walter Reed Army Institute of Research (WRAIR):

Primary Outcome Measures:
  • Difference in degree of hemolysis of G6PD(-) red blood cells in treated vs untreated matched samples.

Estimated Enrollment: 14
Study Start Date: December 2003
Study Completion Date: November 2006

Ages Eligible for Study:   18 Years to 60 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes


  • Normal clinical evaluation
  • Willing and able to make all scheduled visits


  • pregnant or planning pregnancy
  • Have taken any anti-malarial medication in past month
  • Positive blood tests for HIV and specific types of hepatitis
  • Allergic to primaquine
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00076323

United States, Maryland
Walter Reed Army Institute of Research
Silver Spring, Maryland, United States, 20910
Sponsors and Collaborators
Walter Reed Army Institute of Research (WRAIR)
Principal Investigator: Shon A Remich WRAIR, Experimental Therapeutics
  More Information

Additional Information: Identifier: NCT00076323     History of Changes
Other Study ID Numbers: WRAIR 992  G6PD 
Study First Received: January 20, 2004
Last Updated: July 26, 2010
Health Authority: United States: Federal Government

Keywords provided by Walter Reed Army Institute of Research (WRAIR):
G6PD Deficiency
drug reaction
drug-induced hemolysis

Additional relevant MeSH terms:
Glucosephosphate Dehydrogenase Deficiency
Anemia, Hemolytic
Anemia, Hemolytic, Congenital
Carbohydrate Metabolism, Inborn Errors
Genetic Diseases, Inborn
Hematologic Diseases
Metabolic Diseases
Metabolism, Inborn Errors processed this record on May 23, 2016